Topic: Neuroscience

Researchers at the University of Pennsylvania have identified a protein that helps Parkinson's disease spread through the brain. They found that blocking this protein with special antibodies could slow down the disease in its early stages.

Parkinson's disease is a serious condition that affects over one million Americans and approximately 90,000 people in the United States each year. While researchers still don't fully understand what causes the disease, they know it gradually spreads through the brain in stages. A protein called alpha-synuclein plays a central role in this process.

In Parkinson's disease, abnormal clumps of alpha-synuclein form inside neurons, damaging them and causing symptoms like tremors, difficulty walking, balance problems, and trouble swallowing. Current treatments can reduce these symptoms, but there is currently no approved therapy that slows or stops the underlying progression of the disease itself.

Researchers at the Perelman School of Medicine at the University of Pennsylvania have made a breakthrough discovery. They found that a protein called glycoprotein nonmetastatic melanoma B (GPNMB) helps harmful Parkinson's-related damage spread from one brain cell to another. By blocking GPNMB with monoclonal antibodies, they were able to prevent alpha-synuclein pathology from spreading between cells.

The research team analyzed tissue samples from 1,675 brains stored in the Penn Brain Bank and found that individuals carrying genetic variants linked to higher GPNMB production also showed more extensive alpha-synuclein pathology. This provides strong evidence that GPNMB plays a significant role in the progression of Parkinson's disease in humans.

The findings suggest that interrupting this cycle could slow or even stop the spread of alpha-synuclein through the brain and the neurodegeneration that follows.

Why It Matters

This breakthrough discovery offers new hope for developing treatments that can slow down the progression of Parkinson's disease. As the disease affects millions of people worldwide, including many in India, this research has significant implications for improving the lives of those living with Parkinson's.

Key Facts

• Researchers at the University of Pennsylvania identified a protein called glycoprotein nonmetastatic melanoma B (GPNMB) that helps Parkinson's disease spread through the brain.
• Blocking GPNMB with monoclonal antibodies prevented alpha-synuclein pathology from spreading between cells in laboratory experiments.
• The research team analyzed tissue samples from 1,675 brains stored in the Penn Brain Bank and found evidence that GPNMB plays a significant role in the progression of Parkinson's disease in humans.

Key Terms

Glycoprotein nonmetastatic melanoma B (GPNMB)

A protein that helps harmful Parkinson's-related damage spread from one brain cell to another

Implications

This breakthrough discovery offers new hope for developing treatments that can slow down the progression of Parkinson's disease. As the disease affects millions of people worldwide, including many in India, this research has significant implications for improving the lives of those living with Parkinson's.